{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T13:14:09Z","timestamp":1773926049460,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007786","name":"National Center for Child Health and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007786","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K17791"],"award-info":[{"award-number":["22K17791"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jiac.2025.102893","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T16:48:38Z","timestamp":1765471718000},"page":"102893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Does having allergic diseases affect SARS-CoV-2 antibody responses to mRNA vaccination in adolescents?"],"prefix":"10.1016","volume":"32","author":[{"given":"Mayako","family":"Saito-Abe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1288-9620","authenticated-orcid":false,"given":"Kiwako","family":"Yamamoto-Hanada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuki","family":"Fukuie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Ohya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2025.102893_bib1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/21645515.2015.1093263","article-title":"Primary vaccine failure to routine vaccines: why and what to do?","volume":"12","author":"Wiedermann","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jiac.2025.102893_bib2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1081-1206(10)60937-4","article-title":"Childhood asthma and measles vaccine response","volume":"97","author":"Juhn","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jiac.2025.102893_bib3","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/02770903.2019.1575394","article-title":"Relationship between asthma status and antibody response pattern to 23-valent pneumococcal vaccination","volume":"57","author":"Sheen","year":"2020","journal-title":"J Asthma"},{"key":"10.1016\/j.jiac.2025.102893_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0257721","article-title":"Measles antibody seropositivity among children with allergic diseases: a cross-sectional study in the Japan environment & Children's pilot study","volume":"16","author":"Saito-Abe","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jiac.2025.102893_bib5","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1164\/rccm.202111-2496LE","article-title":"Reduced COVID-19 vaccine response in patients treated with biologic therapies for asthma","volume":"205","author":"Runnstrom","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jiac.2025.102893_bib6","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1164\/rccm.202203-0599LE","article-title":"SARS-CoV-2 mRNA vaccine antibody response in patients with asthma receiving biologic therapy: a real-world analysis","volume":"206","author":"Liao","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jiac.2025.102893_bib7","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1183\/09031936.95.08030483","article-title":"International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods","volume":"8","author":"Asher","year":"1995","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jiac.2025.102893_bib8","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2133.1994.tb08530.x","article-title":"The U.K. working Party's diagnostic criteria for atopic dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis","volume":"131","author":"Williams","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jiac.2025.102893_bib9","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.vaccine.2022.03.009","article-title":"Seropositivity to nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: a complementary tool to detect breakthrough infections after COVID-19 vaccination?","volume":"40","author":"van den Hoogen","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.jiac.2025.102893_bib10","first-page":"486","article-title":"SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the Japanese red cross society in 2020","volume":"28","author":"Miyamoto","year":"2022","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2025.102893_bib11","first-page":"3024","article-title":"Age-related immune response heterogeneity to SARS-CoV-2 mRNA vaccination","volume":"13","author":"Hagin","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jiac.2025.102893_bib12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41586-020-2700-3","article-title":"Sex differences in immune responses that underlie COVID-19 disease outcomes","volume":"588","author":"Takahashi","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jiac.2025.102893_bib13","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/s41591-021-01325-6","article-title":"Immune response and booster effectiveness following COVID-19 mRNA vaccination in previously infected individuals","volume":"27","author":"Ebinger","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jiac.2025.102893_bib14","first-page":"543","article-title":"Longitudinal serological analysis and neutralizing antibody levels in COVID-19 convalescents following mRNA vaccination","volume":"15","author":"Choe","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jiac.2025.102893_bib15","article-title":"Immune response durability after SARS-CoV-2 mRNA booster in MS patients","volume":"15","author":"Ziemssen","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jiac.2025.102893_bib17","doi-asserted-by":"crossref","first-page":"876","DOI":"10.3390\/vaccines10060876","article-title":"Immunogenicity of the BNT162b2 COVID-19 vaccine booster dose in healthcare workers","volume":"10","author":"Kontopoulou","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.jiac.2025.102893_bib18","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months","volume":"385","author":"Levin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2025.102893_bib19","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijid.2022.08.022","article-title":"Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers","volume":"123","author":"Brunner","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jiac.2025.102893_bib20","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1001\/jama.2021.15125","article-title":"Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273","volume":"326","author":"Steensels","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jiac.2025.102893_bib21","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","article-title":"Efficacy and safety of an mRNA-Based RSV PreF vaccine in older adults","volume":"389","author":"Wilson","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2025.102893_bib23","author":"Live"},{"key":"10.1016\/j.jiac.2025.102893_bib24","author":"Moderna"},{"key":"10.1016\/j.jiac.2025.102893_bib26","doi-asserted-by":"crossref","first-page":"246","DOI":"10.4103\/0378-6323.16615","article-title":"Correlation of the severity of atopic dermatitis with absolute eosinophil counts in peripheral blood and serum IgE levels","volume":"71","author":"Dhar","year":"2005","journal-title":"Indian J Dermatol, Venereol Leprol"},{"key":"10.1016\/j.jiac.2025.102893_bib27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.0905-6157.2003.00106.x","article-title":"Does the severity of atopic dermatitis correlate with serum IgE levels?","volume":"15","author":"Laske","year":"2004","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jiac.2025.102893_bib28","first-page":"486","article-title":"A multi-centre analysis of serum IgE levels in atopic dermatitis","volume":"69","author":"Yu","year":"2024","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.jiac.2025.102893_bib29","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/j.1365-2133.2010.09904.x","article-title":"Proactive treatment appears to decrease serum immunoglobulin-E levels in patients with severe atopic dermatitis","volume":"163","author":"Fukuie","year":"2010","journal-title":"Br J Dermatol"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25002910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25002910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T09:36:33Z","timestamp":1773912993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X25002910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1341321X25002910"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102893","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does having allergic diseases affect SARS-CoV-2 antibody responses to mRNA vaccination in adolescents?","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102893","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102893"}}